Compare DLTH & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DLTH | MGNX |
|---|---|---|
| Founded | 1989 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 121.1M | 115.8M |
| IPO Year | 2015 | 2013 |
| Metric | DLTH | MGNX |
|---|---|---|
| Price | $2.13 | $1.89 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 1 | 5 |
| Target Price | ★ $7.00 | $3.20 |
| AVG Volume (30 Days) | 38.8K | ★ 533.9K |
| Earning Date | 03-17-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $626,629,000.00 | $149,962,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 155.26 |
| 52 Week Low | $1.58 | $0.99 |
| 52 Week High | $4.66 | $2.49 |
| Indicator | DLTH | MGNX |
|---|---|---|
| Relative Strength Index (RSI) | 45.14 | 57.06 |
| Support Level | $2.10 | $1.62 |
| Resistance Level | $2.36 | $1.97 |
| Average True Range (ATR) | 0.15 | 0.09 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 38.79 | 67.47 |
Duluth Holdings Inc is an apparel brand in the United States. The company offers shirts, pants, and casual wear for men and women under brands like Alaskan Hardgear, Armachillo, Ballroom, Cab Commander, Crouch Gusset, Dry on the Fly, Duluth Trading Co, Duluthflex, Fire Hose, Longtail T, No Polo Shirt, No Yank, Wild Boar, and others. The Company's revenue consists of the sale of apparel, footwear, and hard goods. The company operates in a single operating segment.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.